LGH 2016-36: PALLAS
Recruiting
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is a prospective, two arm, multicenter randomized open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR + / HER2- early breast cancer (EBC).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
13 Nov 2024.
Study ID: 856247
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
